He said because they have no partner it is worth $0... That is absolutely ridiculous! For God's sake, they filed an NDA... It has to be worth more than $0! But then again he assigned a pretty good amount to Regabatin. Which he says may be 8-10 years out... The PDUFA for Rexista is this year. Even with delays it should be out in 2018. But it is worth $0 and a drug that is 8-10 years out- with no partner as well- is worth substantially more!
Yeah, I find that surprising he assign zero value to Rexista. He's logic was that big players are taking the market shares and Rexista would be at a disadvantage enter much later. But, I don't think he realize Rexista is likely superior to those products already out, assuming FDA panel review is positive things can change in favor of IPCI. I do like how success rate was at above 80% but that's just based on other drug approval history.
So we have a good chance to see at least a tentative approval on Rexista.
News 
Market Data 
Discover 
